Retrospective Cohort Study
Copyright ©The Author(s) 2025.
World J Clin Oncol. Apr 24, 2025; 16(4): 100729
Published online Apr 24, 2025. doi: 10.5306/wjco.v16.i4.100729
Table 1 Patient and tumor characteristics
Characteristic
MDTB group (n = 117)
non-MDTB group (n = 276)
P value
Gender, male/female73/44189/870.651
Age, years52.7 ± 17.149.2 ± 15.80.219
Indication for transplantation
    Hepatitis B cirrhosis84 (71.8)208 (75.4)0.662
    Alcoholic cirrhosis18 (15.4)39 (14.1)0.772
    Other15 (12.8)29 (10.5)> 0.990
MELD score at transplantation17.1 ± 4.716.5 ± 4.90.215
PreOP biology
    Total bilirubin, μmol/L79.5 ± 76.974.7 ± 68.20.841
    Serum creatinine, μmol/L86.1 ± 72.682.6 ± 66.30.377
    INR1.4 ± 0.61.5 ± 0.60.447
    Plasma ammonia, μmol/L39.7 ± 21.542.6 ± 23.40.669
    AFP, ng/mL123.4 (7-194)30.1 (7-388)0.165
    PIVKA-II, mAU/mL139.5 (19-372)47.3 (21-463)0.312
Waiting time for LT
    From HCC diagnosis, months3.3 ± 2.62.9 ± 2.50.153
    From listing, days47.8 ± 51.444.7 ± 48.80.571
Radiological characteristics
    Number of nodules2.4 ± 1.32.3 ± 1.30.486
    Size of the largest nodule, mm47.9 ± 18.345.6 ± 17.90.248
    Multifocal tumors41 (35)88 (31.9)0.652
UCSF criteria0.499
    Within UCSF criteria 68 (58.1)171 (61.9)
    Exceeding UCSF criteria49 (41.9)105 (38.1)
Bridging therapy87 (74.4)139 (50.4)0.021
    TACE65 (55.6)86 (31.5)< 0.001
    RFA11 (9.4)28 (10.1)> 0.990
    SBRT2 (1.7)3 (1.1)0.637
    Resection4 (3.4)8 (2.9)0.756
    Other5 (4.3)14 (5.1)> 0.990
Pathological characteristics
    Poorly (Edmonson grade III/IV)56 (47.8)129 (46.7)0.912
    (Micro-) vascular invasion37 (31.6)82 (29.7)0.719
    Capsular invasion33 (28.2)77 (27.9)> 0.990